# BPC-157 TB-500 FAQ: The Wolverine Blend, Answered From the Record > BPC-157 TB-500 FAQ: what the blend is, why the two peptides are paired, whether synergy is proven, side effects and the tumor signal, dosing context, and FDA/WADA status. Direct answers, cited. Twenty-five questions about the Wolverine blend — definition, mechanism, evidence, safety, dosing context, and regulatory status — each answered directly and cited where the claim is quantitative. ## Definition and overview BPC-157 TB-500 questions tend to cluster into a few groups: what the blend is, how the two peptides work, whether the combination is proven, what the side effects are, how it was dosed in animals, and where it stands with the FDA and WADA. This page answers all twenty-five directly. ### What is the Wolverine peptide blend? The Wolverine peptide blend is a research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity or an approved product, and it carries no single molecular weight or CAS number [1][3]. ### What is BPC-157 and TB-500? These are two distinct synthetic peptides combined as a research blend: BPC-157, a 15-amino-acid cytoprotective and angiogenic peptide (GEPPPGKPADDAGLV), and TB-500, an N-acetylated 7-mer (Ac-LKKTETQ) from the actin-binding region of Thymosin Beta-4 [1][3]. ### What is the difference between BPC-157 and TB-500? BPC-157 is a 15-amino-acid gastric-juice-derived cytoprotective and angiogenic peptide; TB-500 is a 7-amino-acid actin-binding fragment of Thymosin Beta-4 acting on cytoskeletal migration [1][3]. Different sequences, different mechanisms. ### What is the BPC-157 and TB-500 blend used for in research? In animal models the constituents have been studied for tendon, ligament, muscle, and wound repair and for angiogenesis [1][2][4]; the blend itself has no controlled human efficacy data [8]. ## Mechanism and the synergy question ### Why are BPC-157 and TB-500 combined (the Wolverine stack)? The rationale pairs BPC-157's cytoprotective and angiogenic signal with TB-500's actin-driven cell-migration signal as complementary mechanisms [2][3]. This "synergy" is a theoretical extrapolation from each peptide's separate mechanism, not a controlled-study finding [8]. ### How does BPC-157 work compared to TB-500? BPC-157 acts as a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS, nitric-oxide modulation), while TB-500 acts intracellularly on actin dynamics [2][3]. The two work through largely non-overlapping pathways. ### How does TB-500 work (actin / Thymosin Beta-4)? TB-500's LKKTETQ motif binds monomeric G-actin 1:1, sequestering it and regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization; structural work on Thymosin Beta-4 established this 1:1 capping mechanism [3]. Most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4, not the 7-mer [4][7]. ### Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)? Both promote angiogenesis by distinct routes in animal and cell models: BPC-157 via VEGFR2-Akt-eNOS up-regulation, and TB-500 / Thymosin Beta-4 via endothelial migration [2][4]. This is preclinical, not a human combination finding. ### Is there any study showing BPC-157 and TB-500 work better together (synergy)? No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together; a 2025 systematic review of BPC-157 makes no mention of TB-500 or combination use [8]. ## Evidence by tissue ### Does the BPC-157 TB-500 blend help tendon and ligament injuries? In rodent models BPC-157 accelerated transected-Achilles-tendon and medial-collateral-ligament healing, and Thymosin Beta-4 improved ligament healing [1][4]; these are animal findings, not human or combination evidence [8]. ### Does BPC-157 and TB-500 help muscle tears and recovery? Preclinical and review evidence describe musculoskeletal-repair effects for BPC-157, but recent reviews rate the evidence at the lowest tiers (level IV-V) with no clinical safety data [8]; nothing addresses the blend in humans. ### Does the BPC-157 TB-500 blend help wound healing? Thymosin Beta-4 accelerated re-epithelialization and wound repair in rodent models and BPC-157 has broad cytoprotective wound data [4]; these are animal and cell findings for the constituents, not human evidence for the blend [8]. ### Are there human clinical trials on the BPC-157 + TB-500 combination? There are no controlled human trials of the combination. Human data exist only for the individual constituents and are thin — three small BPC-157 pilots, and human data for TB-500 that are actually for full-length Thymosin Beta-4 [9][10]. ## Safety ### What are the side effects of BPC-157 and TB-500? Long-term human safety is unknown for both constituents; the main flagged concern is a theoretical tumor and angiogenesis signal for Thymosin Beta-4, and combining two unapproved peptides compounds the uncertainty [4][9]. No controlled safety data exist for the assembled blend [8]. ### Does TB-500 cause cancer or promote tumor growth? Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [5]. This is a flagged safety consideration, not a demonstrated human effect of the blend. ### Is the BPC-157 / TB-500 blend safe for long-term use? No long-term controlled human data exist for either constituent or the blend. The mdx study showed chronic Thymosin Beta-4 produced more regenerating fibers but no gain in strength, cardiac function, or fibrosis reduction [6]; recent reviews rate the human evidence as scarce and treat the compounds as investigational [8][10]. ### What do doctors and reviews say about the BPC-157 + TB-500 blend? Recent reviews are cautious: a 2025 systematic review rated BPC-157 evidence at the lowest tiers (level IV-V) with "no clinical safety data" and no combination mention [8]; a 2026 Sports Medicine review flagged scarce human safety data and potential for serious harm for unapproved musculoskeletal peptides including BPC-157 and TB-500 [9]. ## Dosing context ### What is the half-life of BPC-157 and TB-500? BPC-157's elimination half-life was reported under 30 minutes in animal PK studies [11]; no validated half-life is established for the TB-500 fragment, and none for the blend. ### How do you reconstitute a BPC-157 / TB-500 blend (10mg)? Both are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling [11]; product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [3]. ### How often should you inject BPC-157 and TB-500? There is no validated dosing schedule for the blend; community "loading then maintenance" protocols have no controlled-trial basis and should not be presented as validated dosing [11]. ### How do you cycle BPC-157 and TB-500? No controlled trial defines a cycle for the blend. Community "loading then maintenance" schedules and fixed-ratio vials have no validated basis, and a rat dose-response study found Thymosin Beta-4 effects non-monotonic — higher was not better [4]. ## Regulatory and access ### Are BPC-157 and TB-500 FDA approved or banned by WADA? Neither is FDA-approved for human use; FDA placed BPC-157 in a category of bulk substances not eligible for routine 503A compounding pending review, and both constituents are prohibited by WADA [11][12]. ### Is Wolverine legal? Wolverine is not an approved product, and its two components are FDA Category 2 bulk substances currently restricted for routine 503A pharmacy compounding [12]; both are prohibited in sport by WADA [11]. Both are on the July 23-24, 2026 FDA PCAC agenda as candidates for the 503A bulks list — a scheduled review, not a change in current status [15]. See [Wolverine legal status and 503A compounding](/legal-status) for the full account. ### Can you get BPC-157 from a compounding pharmacy? As of today, BPC-157 is an FDA Category 2 bulk drug substance and is not within FDA's enforcement-discretion policy for routine 503A compounding while that status stands [12][13]. Legally compounded access generally requires a licensed-prescriber evaluation and a valid, patient-specific prescription filled by a 503A pharmacy or 503B facility — only for eligible ingredients, which BPC-157 currently is not [13]. It is on the July 2026 PCAC agenda for evaluation [15]. ### What is the FDA 503A status of Wolverine? Wolverine has no status of its own, but both of its components are FDA Category 2 for 503A compounding, effective with the September 29, 2023 update to the nominated-substances list, on safety-risk grounds [12][13]. Both appear on the July 23-24, 2026 PCAC agenda as substances being considered for inclusion on the 503A bulks list — a scheduled evaluation, not a listing decision [15]. --- Two peptides set on one studio table and shown straight — BPC-157 and TB-500 lit specimen by specimen, the Thymosin Beta-4 tumor signal and the 503A status left in plain view, with no clinic behind the lens and nothing here dispensed.